Böblingen, September 19, 2023 – Wörwag Pharma is taking over contract manufacturer Mauermann-Arzneimittel KG with immediate effect. The Böblingen-based pharmaceutical specialist is thus investing in its own production capacities.
Wörwag Pharma acquires Mauermann-Arzneimittel KG
The acquisition of Mauermann-Arzneimittel KG by the Wörwag Pharma Group of Companies became effective on September 15, 2023. Mauermann is based in Pöcking on Lake Starnberg and has around 60 employees there. The contract manufacturer is GMP (Good Manufacturing Practice)-certified for the production and packaging of solid dosage forms and produces milgamma® and magnerot® for Wörwag Pharma, among others.
The two family-owned companies have enjoyed a trusting cooperation for more than 45 years, which will now be taken to the next level through the acquisition. Gerhard Mayer, Chief Financial Officer of Wörwag Pharma, explains: "At Wörwag Pharma, we have ambitious growth targets – and Mauermann was looking for an investor and is also one of our most important suppliers. Reliability, customer orientation and family focus are values that unite us. We are all the more pleased that we can now grow even closer together and further develop Mauermann's business."
Mauermann is Wörwag Pharma's second own production site: the Polish city of Lodz is home to Wörwag Pharma Operations, the company's first own production facility, which was acquired in 2021 and has since been fully integrated into the group of companies.
The headquarters of Mauermann-Arzneimittel KG in Pöcking, Bavaria